COMPANY
Epoulosis Therapeutics, Inc.
Funding and NIH signals
- NIH award NIH awarded $1.01M (SBIR Phase II 5R44DK141401-02, continuation, notice Jul 22, 2026). NIH RePORTER 5R44DK141401-02 (Jul 22, 2026)
Evidence (1 event)
- Jul 22, 2026 · NIH RePORTER 5R44DK141401-02
Organization: EPOULOSIS THERAPEUTICS, INC.; City/State: NEWTON, MA; Project number: 5R44DK141401-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 1012588; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Metrifonate local application for DFU treatment; Organization type: Domestic For-Profits
- Jul 22, 2026 · NIH RePORTER 5R44DK141401-02